Literature DB >> 21443466

FOXO1: a potential target for human diseases.

Huarui Lu1, Haojie Huang.   

Abstract

The forkhead box O (FoxO) transcription factors are known to be involved in many physiological and pathological processes including apoptosis, cell cycle arrest, stress resistance, glucose metabolism, cellular differentiation and development, and tumor suppression. The environmental cues, such as growth factors, nutrients, oxidative stress and irradiation, can either positively or negatively modulate FoxO proteins' activities, thereby ensuring distinctive transcription programs in the cell. The potent activities of FoxOs are tightly controlled by multiple mechanisms, which include posttranslational modification such as phosphorylation, acetylation, methylation and ubiquitination, subcellular localization, and direct protein-protein interaction. Mounting evidence suggests that the human FOXO1 protein, a founding member of the FoxO family is likely involved in carcinogenesis, diabetes and other human diseases. Here we give an overview of most recent findings regarding the regulation and function of FoxO1, its potential role in human diseases and useful animal models for functional studies on FoxO1. Prospective ways in which the discoveries from the basic research of FoxO1 can be utilized for drug targeting and development of novel therapeutics for human diseases are also discussed.
© 2011 Bentham Science Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443466      PMCID: PMC4591039          DOI: 10.2174/138945011796150280

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  104 in total

1.  The forkhead transcription factor Foxo1 regulates adipocyte differentiation.

Authors:  Jun Nakae; Tadahiro Kitamura; Yukari Kitamura; William H Biggs; Karen C Arden; Domenico Accili
Journal:  Dev Cell       Date:  2003-01       Impact factor: 12.270

2.  The transcriptional coactivators p300 and CBP are histone acetyltransferases.

Authors:  V V Ogryzko; R L Schiltz; V Russanova; B H Howard; Y Nakatani
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

3.  Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).

Authors:  A Brunet; J Park; H Tran; L S Hu; B A Hemmings; M E Greenberg
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

4.  Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis.

Authors:  Min-Seon Kim; Youngmi K Pak; Pil-Geum Jang; Cherl Namkoong; Yon-Sik Choi; Jong-Chul Won; Kyung-Sup Kim; Seung-Whan Kim; Hyo-Soo Kim; Joong-Yeol Park; Young-Bum Kim; Ki-Up Lee
Journal:  Nat Neurosci       Date:  2006-06-18       Impact factor: 24.884

5.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Authors:  Haojie Huang; Kevin M Regan; Fang Wang; Diping Wang; David I Smith; Jan M A van Deursen; Donald J Tindall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

6.  Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control.

Authors:  Yasutomi Kamei; Shinji Miura; Miki Suzuki; Yuko Kai; Junko Mizukami; Tomoyasu Taniguchi; Keiji Mochida; Tomoko Hata; Junichiro Matsuda; Hiroyuki Aburatani; Ichizo Nishino; Osamu Ezaki
Journal:  J Biol Chem       Date:  2004-07-21       Impact factor: 5.157

7.  Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells.

Authors:  Haojie Huang; David C Muddiman; Donald J Tindall
Journal:  J Biol Chem       Date:  2004-01-15       Impact factor: 5.157

8.  Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

Authors:  Lu Gan; Shuai Chen; Yuwei Wang; Akira Watahiki; Laura Bohrer; Zhen Sun; Yuzhuo Wang; Haojie Huang
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

9.  The obesity susceptibility gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake.

Authors:  Leona Plum; Hua V Lin; Roxanne Dutia; Jun Tanaka; Kumiko S Aizawa; Michihiro Matsumoto; Andrea J Kim; Niamh X Cawley; Ji-Hye Paik; Y Peng Loh; Ronald A DePinho; Sharon L Wardlaw; Domenico Accili
Journal:  Nat Med       Date:  2009-09-20       Impact factor: 53.440

10.  Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity.

Authors:  Atsushi Tsuchida; Toshimasa Yamauchi; Yusuke Ito; Yusuke Hada; Toshiyuki Maki; Sato Takekawa; Junji Kamon; Masaki Kobayashi; Ryo Suzuki; Kazuo Hara; Naoto Kubota; Yasuo Terauchi; Philippe Froguel; Jun Nakae; Masato Kasuga; Domenico Accili; Kazuyuki Tobe; Kohjiro Ueki; Ryozo Nagai; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

View more
  20 in total

1.  Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer.

Authors:  Doo Byung Chay; Gwan Hee Han; Sanghee Nam; Hanbyoul Cho; Joon-Yong Chung; Stephen M Hewitt
Journal:  Int J Clin Oncol       Date:  2019-07-13       Impact factor: 3.402

2.  Identification of enhancer regulatory elements that direct epicardial gene expression during zebrafish heart regeneration.

Authors:  Yingxi Cao; Yu Xia; Joseph J Balowski; Jianhong Ou; Lingyun Song; Alexias Safi; Timothy Curtis; Gregory E Crawford; Kenneth D Poss; Jingli Cao
Journal:  Development       Date:  2022-02-18       Impact factor: 6.868

Review 3.  Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways.

Authors:  Usman Sabir; Hafiz Muhammad Irfan; Ihtisham Umer; Zahid Rasul Niazi; Hafiz Muhammad Mazhar Asjad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-31       Impact factor: 3.000

Review 4.  Forkhead Box Protein O1: Functional Diversity and Post-Translational Modification, a New Therapeutic Target?

Authors:  Xiaojun Zhang; Lusheng Jiang; Huimin Liu
Journal:  Drug Des Devel Ther       Date:  2021-05-03       Impact factor: 4.162

5.  CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.

Authors:  Xuejiao Liu; Yulong Chong; Yiming Tu; Ning Liu; Chenglong Yue; Zhenglei Qi; Huize Liu; Yao Yao; Hongmei Liu; Shangfeng Gao; Mingshan Niu; Rutong Yu
Journal:  J Hematol Oncol       Date:  2016-10-12       Impact factor: 17.388

6.  miR-486 inhibits PM2.5-induced apoptosis and oxidative stress in human lung alveolar epithelial A549 cells.

Authors:  Jin Li; Qiulian Zhou; Yajun Liang; Wen Pan; Yihua Bei; Yuhui Zhang; Jinhua Wang; Zheng Jiao
Journal:  Ann Transl Med       Date:  2018-06

7.  Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway.

Authors:  Hong-Ming Song; Jia-Lu Song; Deng-Feng Li; Kai-Yao Hua; Bing-Kun Zhao; Lin Fang
Journal:  Onco Targets Ther       Date:  2015-12-01       Impact factor: 4.147

8.  High cytoplasmic FOXO1 and pFOXO1 expression in astrocytomas are associated with worse surgical outcome.

Authors:  Chao Chen; Tao Xu; Jinxu Zhou; Yong Yan; Weiqing Li; Hongyu Yu; Guohan Hu; Xuehua Ding; Juxiang Chen; Yicheng Lu
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation.

Authors:  Yan-Fang Tao; Li-Xiao Xu; Jun Lu; Lan Cao; Zhi-Heng Li; Shao-Yan Hu; Na-Na Wang; Xiao-Juan Du; Li-Chao Sun; Wen-Li Zhao; Pei-Fang Xiao; Fang Fang; Yan-Hong Li; Gang Li; He Zhao; Yi-Ping Li; Yun-Yun Xu; Jian Ni; Jian Wang; Xing Feng; Jian Pan
Journal:  J Transl Med       Date:  2014-06-25       Impact factor: 5.531

Review 10.  Marine Sponge Natural Products with Anticancer Potential: An Updated Review.

Authors:  Cinzia Calcabrini; Elena Catanzaro; Anupam Bishayee; Eleonora Turrini; Carmela Fimognari
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.